Friday, February 17, 2012

The skinny on Vivus obesity drug: safety issues, FDA says

Ahead of a Feb. 22 advisory panel meeting for Vivus Inc. weight-loss drug Qnexa, a report from Food and Drug Administration staff cited safety concerns about the treatment.
The stock of Mountain View-based Vivus (NASDAQ: VVUS) was up 3 percent to $11.53 per share by late afternoon Friday.
If approved, Qnexa would be the first new prescription drug approved for weight loss in more than a decade.

No comments:

Post a Comment